tirzepatide and cardiovascular outcomes Long-awaited SURPASS-CVOT: with vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, kidney function Tirzepatide linked to lower risk
Pay in 4 interest-free payments of $5.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23




























![Trulicity Lawsuit [2026]](https://www.torhoermanlaw.com/wp-content/uploads/2026/02/Trulicity-Lawsuit-768x384.jpg)

